Kymera Results Presentation Deck

● ● ● ● Demonstration of Initial Proof-of-Mechanism (POM) for KT-333 Accrual to first dose level completed STAT3 degradation in blood at first dose level consistent with preclinical predictions, with mean maximum degradation following first 2 doses of Cycle 1 averaging 66%, with maximum knockdown of up to 86% At least 48h of target degradation observed that in preclinical species led to robust antitumor activity in STAT3 sensitive preclinical models DL1 level generally well-tolerated with no DLTS or treatment-related SAEs DL2 currently enrolling patients DL3-4 expected to be clinically active doses KYMERA ©2022 KYMERA THERAPEUTICS, INC. PAGE 14

View entire presentation